Shanghai Shyndec Pharmaceutical Faces Declining Sales and Rising Costs Amid Market Challenges

Shanghai Shyndec Pharmaceutical Co., Ltd. has recently undergone an adjustment in evaluation, reflecting a shift in its market position and performance indicators. The company operates within the Pharmaceuticals & Biotechnology sector and is classified as a large-cap entity. Recent data highlights a decline in net sales, which has contracted at an annual rate of 4.13% over the past five years. In the latest quarter ending June 2025, the company reported a significant drop in net sales by 13.01%, contributing to a series of negative results over the last two consecutive quarters. Additionally, the operating cash flow has reached its lowest point at CNY 770.77 million, while raw material costs have surged by 102.84% year-over-year. The technical indicators present a mixed picture, with the MACD showing a mildly bullish trend on a weekly basis but bearish on a monthly basis. The overall technical trend has shifted to bearish, indicating a cautious outlook. This evaluation adjustment underscores the challenges faced by Shanghai Shyndec Pharmaceutical Co., Ltd. in maintaining its competitive edge in a dynamic market environment. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.